Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Merck & Company (MRK)

Merck & Company (MRK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 244,210,960
  • Shares Outstanding, K 2,529,635
  • Annual Sales, $ 60,115 M
  • Annual Income, $ 365,000 K
  • EBIT $ 14,160 M
  • EBITDA $ 18,032 M
  • 60-Month Beta 0.40
  • Price/Sales 4.06
  • Price/Cash Flow 31.74
  • Price/Book 5.49

Options Overview Details

View History
  • Implied Volatility 23.63% ( +0.74%)
  • Historical Volatility 17.13%
  • IV Percentile 85%
  • IV Rank 56.08%
  • IV High 30.32% on 10/28/24
  • IV Low 15.09% on 05/17/24
  • Put/Call Vol Ratio 0.34
  • Today's Volume 18,822
  • Volume Avg (30-Day) 37,774
  • Put/Call OI Ratio 0.75
  • Today's Open Interest 395,204
  • Open Int (30-Day) 397,635

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 26 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 1.86
  • Number of Estimates 7
  • High Estimate 2.13
  • Low Estimate 1.63
  • Prior Year 0.03
  • Growth Rate Est. (year over year) +6,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
94.48 +3.13%
on 11/15/24
109.17 -10.74%
on 10/21/24
-11.26 (-10.36%)
since 10/18/24
3-Month
94.48 +3.13%
on 11/15/24
120.30 -19.00%
on 09/06/24
-17.70 (-15.37%)
since 08/20/24
52-Week
94.48 +3.13%
on 11/15/24
134.63 -27.62%
on 06/25/24
-5.24 (-5.10%)
since 11/20/23

Most Recent Stories

More News
Pharma Stock Roundup: AZN, BAYRY's Earnings, ABBV's Pipeline Setback

The third-quarter earnings season came to an end this week for large drugmakers, with AstraZeneca AZN and Bayer BAYRY announcing their results. AbbVie’s ABBV schizophrenia candidate, added from a recent...

BAYRY : 5.1400 (-4.10%)
AZN : 63.20 (-0.94%)
JNJ : 153.11 (+0.07%)
MRK : 97.44 (+0.93%)
ABBV : 167.76 (+0.71%)
Why Are These 3 Vanguard ETFs Underperforming the S&P 500 Since Election Day?

Stocks in these "safe" sectors are selling off as investors gravitate toward growth.

MO : 55.98 (+0.21%)
VHT : 263.01 (+1.06%)
KO : 62.99 (+0.64%)
MRK : 97.44 (+0.93%)
JNJ : 153.11 (+0.07%)
UNH : 600.50 (+4.07%)
COMP : 6.44 (+2.22%)
COST : 928.08 (-0.22%)
VDC : 215.28 (-0.17%)
PG : 170.89 (+0.08%)
LLY : 753.41 (+3.25%)
VPU : 173.77 (+0.09%)
3 Stocks Poised for a Breakout

All 3 stocks are high on my watchlist.

MRK : 97.44 (+0.93%)
RBLX : 51.52 (-1.38%)
UBER : 69.60 (+0.68%)
MarketBeat Week in Review – 11/4 - 11/8

Markets rallied strongly this week on clarity about the election and an expected rate cut, but next week's inflation readings will determine if momentum lasts

NVDA : 145.89 (-0.76%)
SMMT : 18.62 (-6.90%)
MRK : 97.44 (+0.93%)
ALT : 8.05 (+7.76%)
ENVX : 9.01 (+0.90%)
CCL : 25.08 (-0.20%)
COIN : 320.01 (-1.40%)
BMY : 57.88 (-0.60%)
FSLR : 184.84 (-1.35%)
SOUN : 6.44 (-1.08%)
QCOM : 154.27 (-6.34%)
INTC : 24.01 (-0.79%)
Canada's Drug Agency Recommends WINREVAIR® (sotatercept) for Reimbursement

/CNW/ - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that Canada's Drug Agency (CDA) has recommended WINREVAIR®...

MRK : 97.44 (+0.93%)
2 Hot Biopharma Stocks to Buy and Hold for 5 Years

If you're patient, these businesses have a lot of promising projects in the works.

SMMT : 18.62 (-6.90%)
MRK : 97.44 (+0.93%)
Got $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows.

These stocks have seen better days but investors shouldn't count them out in the long run.

DG : 73.27 (-4.22%)
MRK : 97.44 (+0.93%)
NKE : 73.36 (-0.74%)
Stocks and ETFs in Focus as Americans Head to Polls

Election Day has approached, and the polls indicate a tight race between Democratic Party candidate Kamala Harris and Republican nominee Donald Trump. Neither candidate holds a meaningful edge in enough...

KBWB : 68.46 (-0.23%)
BE : 24.80 (+4.42%)
CVX : 161.33 (+1.08%)
JPM : 240.78 (-0.95%)
MRK : 97.44 (+0.93%)
IHE : 67.40 (+1.06%)
PPH : 87.44 (+0.66%)
UNH : 600.50 (+4.07%)
PFE : 24.94 (-0.64%)
KBH : 77.97 (+0.19%)
XLE : 96.34 (+1.01%)
XHB : 116.55 (+1.00%)
2 Magnificent Stocks to Buy That Are Near 52-Week Lows

These stocks near 52-week lows could be ready to rebound.

MRK : 97.44 (+0.93%)
PFE : 24.94 (-0.64%)
Should Moderna Stock Be in Your Portfolio Pre-Q3 Earnings?

Moderna MRNA is set to report third-quarter 2024 earnings on Nov. 7, before the opening bell. The Zacks Consensus Estimate for sales and earnings is pegged at $1.25 billion and a loss of $1.91 per share,...

MRK : 97.44 (+0.93%)
MRNA : 36.94 (-0.94%)
GSK : 33.35 (-0.33%)
PFE : 24.94 (-0.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda,...

See More

Key Turning Points

3rd Resistance Point 100.81
2nd Resistance Point 99.83
1st Resistance Point 98.63
Last Price 97.44
1st Support Level 96.45
2nd Support Level 95.47
3rd Support Level 94.27

See More

52-Week High 134.63
Fibonacci 61.8% 119.29
Fibonacci 50% 114.56
Fibonacci 38.2% 109.82
Last Price 97.44
52-Week Low 94.48

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar